The standard clinical dosing of tesamorelin used in human studies and in approved medical treatment is 2 mg once daily administered via subcutaneous injection, typically into the abdominal area [1–7]. This 2 mg daily dose has been consistently employed across Phase II, Phase III, and long-term studies of tesamorelin in the context of HIV-related lipodystrophy, visceral fat reduction, and non-alcoholic fatty liver disease (NAFLD).
Tesamorelin is a synthetic version of growth hormone-releasing hormone (GHRH), a natural hormone that signals the pituitary gland to release growth hormone (GH) [1,2]. By increasing natural GH production, tesamorelin also raises levels of insulin-like growth factor-1 (IGF-1). Clinical studies show that a dose of 2 mg per day can significantly increase IGF-1 levels while decreasing visceral abdominal fat and improving several metabolic markers without causing significant disturbances in blood sugar control in most participants.
Early dose-finding studies tested various doses of tesamorelin to determine the most effective treatment protocol. In a placebo-controlled study conducted by Falutz J et al. (2005), HIV-positive individuals with abdominal fat accumulation received a placebo, 1 mg of tesamorelin, or 2 mg of tesamorelin daily for 12 weeks [3]. Both doses of tesamorelin increased IGF-1 levels, but the 2 mg dose resulted in a greater reduction in visceral fat, trunk fat, and triglyceride levels. Participants in the 2 mg group achieved approximately a 15.71% reduction in visceral abdominal fat, which helped establish 2 mg daily as the preferred clinical dose.
Later Phase III clinical trials standardized the protocol of 2 mg once daily. Falutz J et al. (2010) studied tesamorelin at a dose of 2 mg daily in 806 HIV-positive individuals with excess abdominal fat and reported a significant reduction in visceral adipose tissue and waist circumference over 26 to 52 weeks [4]. Visceral adipose tissue refers to deep-seated fat stored around internal organs in the abdominal cavity. Similar dosing was also used in studies by Stanley TL et al. (2014) and Stanley TL et al. (2019), which analyzed the effect of tesamorelin on reducing HIV-associated liver fat and NAFLD [5,6].
Most research protocols provide tesamorelin as a daily subcutaneous injection into the abdominal area. A subcutaneous injection means administering the medication into the fatty tissue directly beneath the skin. Clinical trials typically ranged from 26 weeks to 12 months, and evidence suggests that continued treatment may be necessary to maintain visceral fat reduction [4,7]. Participants who discontinued treatment often regained abdominal fat after cessation of therapy.
Tesamorelin is typically supplied as a lyophilized powder, meaning it is freeze-dried for stability and must be mixed with sterile or bacteriostatic water before injection [1,2]. After reconstitution, the prescribed dose is administered subcutaneously, usually with rotation of injection sites around the abdomen to minimize irritation.
Current scientific evidence does not support the use of significantly higher doses than 2 mg daily in standard clinical practice. Most published human trials examining body composition, liver fat, metabolic health, and cognitive function consistently use a 2 mg once-daily regimen as it appears to provide a balance between efficacy, safety, and tolerability [3–7].
How often should Tesamorelin be injected?
Tesamorelin is most commonly given once daily by subcutaneous injection, and nearly all clinical trials in humans evaluating tesamorelin have used a dosing regimen of 2 mg once daily [1–6]. Studies consistently show that daily administration is necessary to maintain growth hormone-releasing hormone (GHRH) pathway activity and preserve reduction in visceral abdominal and liver fat over time.
Clinical trials analyzing tesamorelin in the context of HIV-associated lipodystrophy, excess abdominal fat, and non-alcoholic fatty liver disease (NAFLD) have consistently employed daily dosing protocols. In Phase III trials conducted by Falutz J et al. (2010), participants injected 2 mg of tesamorelin once daily for 26 weeks, with many continuing treatment for up to 52 weeks [1]. During this period, researchers observed significant reductions in visceral adipose tissue, waist circumference, and triglyceride levels. Visceral adipose tissue refers to deep-seated fat stored around internal organs within the abdominal cavity.
Similarly, Stanley TL et al. (2014) and Stanley TL et al. (2019) used daily tesamorelin injections for periods of 6 to 12 months in studies analyzing the reduction of abdominal and liver fat [2,3]. These studies showed that regular daily dosing led to a significant decrease in visceral fat and liver fat accumulation.
Research also suggests that missing doses or discontinuing tesamorelin may limit or reverse some of its benefits over time. In the long-term study by Falutz J et al. (2008), participants who discontinued daily tesamorelin injections gradually regained visceral abdominal fat, while those who continued daily treatment maintained their obtained results [4]. This indicates that continuous daily stimulation of the natural growth hormone pathway is important for maintaining metabolic changes and improving body composition.
Tesamorelin is administered as a subcutaneous injection, meaning the medication is injected into the fatty tissue just under the skin, typically in the abdominal area [1,2]. Most research protocols recommend rotating injection sites to help minimize irritation or injection site reactions. In studies, tesamorelin was also often given around the same time each day to maintain more stable hormone signaling patterns.
Current clinical evidence does not support weekly or intermittent dosing schedules for tesamorelin. Published human studies examining the impact of tesamorelin on body composition, metabolism, visceral fat, and hepatic fat have consistently utilized daily administration protocols, rather than less frequent dosing [1–6].
Best time for Tesamorelin: morning or evening?
Tesamorelin is most commonly used once daily, with many clinicians and treatment protocols preferring administration in the evening or at night, as the body's natural growth hormone (GH) secretion peaks during sleep [1–4]. While most clinical studies have focused more on the daily dosage rather than the exact timing of injection, evening use is often recommended to better align with the body's natural circadian rhythm, the internal biological clock that controls hormone release throughout the day and night.
Tesamorelin works by mimicking growth hormone-releasing hormone (GHRH), a natural hormone that signals the pituitary gland to increase the secretion of endogenous growth hormone, which is growth hormone produced naturally by the body [1,2]. As GH levels increase, insulin-like growth factor-1 (IGF-1) levels also increase. In healthy individuals, the largest natural GH surges typically occur during deep sleep, particularly in the first part of the night. For this reason, many protocols recommend taking tesamorelin in the evening or before bedtime so that its effects can better synchronize with the body's natural nocturnal GH release rhythm.
Clinical studies analyzing tesamorelin in the context of HIV-associated lipodystrophy and visceral abdominal fat reduction have typically used once-daily injections without a direct comparison of morning versus evening administration [3–6]. In phase III trials conducted by Falutz J et al. (2010), participants received 2 mg daily and experienced significant reductions in visceral abdominal fat along with improvements in metabolic markers [3]. Visceral fat refers to deep fat stored around internal organs. Similarly, Stanley TL et al. (2019) administered tesamorelin once daily for 12 months to individuals with HIV-associated non-alcoholic fatty liver disease (NAFLD) and noted significant reductions in liver fat [4].
Although there is a limited number of studies directly comparing morning and evening tesamorelin injections, evening dosing is often preferred as it may better align with natural growth hormone secretion patterns and the overnight fasting period. Some clinicians also suggest taking tesamorelin on a relatively empty stomach, as high insulin and blood sugar levels may blunt the body's natural GH release response.
Research suggests that regular daily use of tesamorelin is the most important factor, rather than focusing solely on the exact time of administration. Clinical studies have repeatedly shown that regular daily administration of tesamorelin for several months is associated with a reduction in visceral fat, waist circumference, liver fat, and markers of metabolic risk [3-6].
Different people may tolerate different dosing times differently depending on sleep quality, appetite, energy levels, work schedule, or comfort with performing injections. Some people prefer evening injections due to a theoretical link with the natural nocturnal rhythm of GH secretion, while others choose morning injections simply because it is easier for them to maintain regularity each day.
Disclaimer
The content is for educational and scientific informational purposes only. It should not be interpreted as medical advice, diagnosis, or therapeutic recommendations. Tesamorelin is a prescription medication primarily approved for the treatment of HIV-associated lipodystrophy. Hormone therapies affecting growth hormone and IGF-1 pathways require medical supervision, laboratory monitoring, and individual clinical assessment by a qualified healthcare professional.